Back to top
more

Dentsply Sirona (XRAY)

(Real Time Quote from BATS)

$26.22 USD

26.22
698,890

-0.17 (-0.64%)

Updated Jul 23, 2024 03:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (160 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up

Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.

Stryker (SYK) Earnings and Revenues Miss Estimates in Q1

Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.

InMode (INMD) to Report Q1 Earnings: What's in the Offing?

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q1

Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.

Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates

Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong

The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates

Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.

Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid

Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.

Here's Why You Should Retain Stryker (SYK) Stock Right Now

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako and broad product portfolio. However, pricing pressure raises a concern.

Veeva Systems (VEEV) Inks Deal to Advance Clinical Trials

Veeva Systems (VEEV) collaborates with Parexel to accelerate clinical trials by combining the best of each company's experience.

Here's Why You Should Hold on to LabCorp (LH) Stock Now

Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.

Urmimala Biswas headshot

MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

Medtronic (MDT) Boosts Diabetes Management via New Infusion Set

Medtronic's (MDT) recently introduced Medtronic Extended infusion set with longer wearability enhances convenience and comfort, thus improving diabetes care.

Trina Mukherjee headshot

Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch

Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.

XRAY vs. ALGN: Which Stock Is the Better Value Option?

XRAY vs. ALGN: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to NEOGEN (NEOG) Stock for Now

Investors continue to be optimistic about NEOGEN (NEOG) on robust segmental and geographical growth.

Bruker Corporation (BRKR) Reports Solid Preliminary Q1 Revenues

Bruker's (BRKR) revenue improvement in the first quarter is likely to have been boosted by robust performance by all three of its BSI groups.

PRA Health (PRAH) Chosen by MedChi to Offer Telehealth Services

PRA Health's (PRAH) company, Care Innovations, gets selected by MedChi to provide remote patient monitoring services, thereby enabling better patient care.

Reasons to Hold on to Align Technology (ALGN) Stock for Now

Investors continue to be optimistic about Align Technology (ALGN) on solid customer adoption of Invisalign and iTero products.

Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B

Luminex (LMNX) to be acquired by DiaSorin for around $1.8 billion. This is likely to advance its technology and solutions' foothold outside the United States.

Here's Why You Should Hold on to Cardinal Health (CAH) Stock

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.

Here's Why You Should Add Phibro (PAHC) to Your Portfolio

Investors continue to be optimistic about Phibro (PAHC), owing to its potential in Performance Products and consistent high demand for its nutritional specialty products.

Globus Medical (GMED) Hurt by Dull Global Growth, Low Margins

Pricing continues to remain a major headwind for Globus Medical (GMED).

Omnicell's (OMCL) Automated Dispensing Service Adopted by Aultman

Omnicell's (OMCL) Autonomous Pharmacy vision receives another boost with the latest service adoption by Aultman.